Manus Bio website screenshot

Manus Bio

Manus Bio Inc. (trading as "Manus", the BioAlternatives Company) is a Cambridge, Massachusetts industrial biotechnology company founded in 2011 out of MIT by Dr. Aji Parayil and Dr. Greg Stephanopoulos. Manus engineers microbial cell factories and precision-fermentation processes so that complex molecules normally obtained through petrochemical synthesis, agricultural extraction, or animal husbandry can be produced by fermentation instead - what the company calls bioalternatives. Its commercialized products include the first U.S. commercial-scale monk fruit sweetener (produced at its Augusta, Georgia BioFacility), the Yume M stevia Reb M sweetener co-developed with Tate & Lyle, citrus-derived aroma ingredients (Nootkatone 70, Valencene 80, BioNootkatone) for Givaudan, and an artemisinin antimalarial program funded by HHS/ASPR. It sells scale-up services through its BioAccelerator and BioManufacturing programs (protein engineering, strain development, bioprocess development from 250 ml to 3,000 L, pilot-scale and biomanufacturing). In April 2025 Manus merged with genome-engineering company Inscripta, adding whole-genome editing technology and the MAD7 CRISPR nuclease licensing program; inscripta.com is now a redirect notice. Manus is a manufacturer of physical ingredients and a contract development and manufacturing organization - it sells molecules and services, not software. It publishes no public API, developer portal, SDK, webhook surface, or machine-readable specification of any kind, and its computational and AI-driven enzyme-engineering tools are internal capabilities that support its services rather than a customer-facing platform.

Manus Bio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Synthetic Biology, Biomanufacturing, and Industrial Biotechnology.

Manus Bio’s developer surface includes engineering blog and 8 more developer resources.

11.4/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0
0 APIs
CompanyBiotechnologySynthetic BiologyBiomanufacturingIndustrial BiotechnologyPrecision FermentationIngredientsFood and BeverageSustainabilityLife Sciences

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0
Composite quality — 11.4/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.4 / 17
Commercial Clarity 3.6 / 17
Operational Transparency 0.6 / 11
Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 2.6 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/manus-bio: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Manus Bio Domain Security

TLSv1.3 · HSTS · DMARC

SECURITY

Resources

Build 1

SDKs, sample code, and the tooling you integrate with

Access & Security 1

Authentication, authorization, and security posture

Operate 1

Status, limits, changes, and where to get help

Commercial 2

Pricing, plans, and the legal terms of use

Company 4

The organization behind the API

Source (apis.yml)

apis.yml Raw ↑
aid: manus-bio
name: Manus Bio
image: https://cdn.prod.website-files.com/6536fe08e98c41581598326f/6682ee89aa355ed6e2dca105_Manus%20Social%20Image.png
description: Manus Bio Inc. (trading as "Manus", the BioAlternatives Company) is a Cambridge, Massachusetts industrial biotechnology
  company founded in 2011 out of MIT by Dr. Aji Parayil and Dr. Greg Stephanopoulos. Manus engineers microbial cell factories
  and precision-fermentation processes so that complex molecules normally obtained through petrochemical synthesis, agricultural
  extraction, or animal husbandry can be produced by fermentation instead - what the company calls bioalternatives. Its commercialized
  products include the first U.S. commercial-scale monk fruit sweetener (produced at its Augusta, Georgia BioFacility), the
  Yume M stevia Reb M sweetener co-developed with Tate & Lyle, citrus-derived aroma ingredients (Nootkatone 70, Valencene
  80, BioNootkatone) for Givaudan, and an artemisinin antimalarial program funded by HHS/ASPR. It sells scale-up services
  through its BioAccelerator and BioManufacturing programs (protein engineering, strain development, bioprocess development
  from 250 ml to 3,000 L, pilot-scale and biomanufacturing). In April 2025 Manus merged with genome-engineering company Inscripta,
  adding whole-genome editing technology and the MAD7 CRISPR nuclease licensing program; inscripta.com is now a redirect notice.
  Manus is a manufacturer of physical ingredients and a contract development and manufacturing organization - it sells molecules
  and services, not software. It publishes no public API, developer portal, SDK, webhook surface, or machine-readable specification
  of any kind, and its computational and AI-driven enzyme-engineering tools are internal capabilities that support its services
  rather than a customer-facing platform.
url: https://raw.githubusercontent.com/api-evangelist/manus-bio/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-source-url: https://forgeglobal.com/manus-bio_stock/
x-tier: stub
x-tier-reason: harvest
x-status: active
x-merged-with: inscripta
x-merged-date: 2025-04
x-references:
- name: 'Manus: Manus and Inscripta merge to create a leader in industrial biomanufacturing'
  url: https://www.manusbio.com/articles/manus-and-inscripta-merge-to-create-a-leader-in-industrial-biomanufacturing
- name: 'Manus: Made in America - the first monk fruit sweetener produced in the U.S. at commercial scale'
  url: https://www.manusbio.com/articles/made-in-america-manus-unveils-the-first-monk-fruit-sweetener-produced-in-the-u-s-at-commercial-scale
- name: 'CU Boulder Venture Partners: Inscripta Inc. (now Manus Bio Inc.)'
  url: https://www.colorado.edu/venturepartners/startup-portfolio/inscripta-inc-now-manus-bio-inc
specificationVersion: '0.20'
created: '2026-08-04'
modified: '2026-08-04'
tags:
- Company
- Biotechnology
- Synthetic Biology
- Biomanufacturing
- Industrial Biotechnology
- Precision Fermentation
- Ingredients
- Food and Beverage
- Sustainability
- Life Sciences
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  name: Manus
  url: https://www.manusbio.com/
- type: About
  name: About Manus
  url: https://www.manusbio.com/about
- type: Blog
  name: Insights and News
  url: https://www.manusbio.com/insights-and-news
- type: Contact
  name: Contact
  url: https://www.manusbio.com/contact
- type: Careers
  name: Careers
  url: https://www.manusbio.com/careers
- type: TermsOfService
  name: Terms and Conditions
  url: https://www.manusbio.com/terms-and-conditions
- type: PrivacyPolicy
  name: Cookie and Privacy Policy
  url: https://www.manusbio.com/cookie-and-privacy-policy
- type: GitHubOrganization
  name: ManusBio on GitHub
  url: https://github.com/ManusBio
  description: Organization account exists (created 2025-08-22) but publishes zero public repositories.
- type: DomainSecurity
  name: Domain Security
  url: security/manus-bio-domain-security.yml
x-enrichment:
  date: '2026-08-04'
  status: minimal
  artifacts_added: 1
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Manus sells fermentation-produced ingredients and contract biomanufacturing services, not software; its Webflow
    marketing site returns 404 for every contract-discovery path, no api./docs./developer. subdomain resolves, and the github.com/ManusBio
    organization has zero public repositories.
  evidence:
  - url: https://www.manusbio.com/openapi.json
    status: 404
  - url: https://www.manusbio.com/llms.txt
    status: 404
  - url: https://www.manusbio.com/.well-known/security.txt
    status: 404
  - url: https://www.manusbio.com/.well-known/agent-card.json
    status: 404
  - url: https://www.manusbio.com/.well-known/agent.json
    status: 404
  - url: https://www.manusbio.com/sitemap.xml
    status: 200
  - url: https://www.inscripta.com/
    status: 200
  - url: https://api.github.com/orgs/manusbio
    status: 200
  checked: '2026-08-04'